PharmiWeb.com - Global Pharma News & Resources
14-Nov-2022

Non-Invasive Prenatal Testing Market is anticipated to expand at a CAGR of 16% between 2023 and 2032

The market for Non-Invasive Prenatal Testing was valued at US$ 3.3 billion in 2021, and between 2023 and 2032 it is anticipated to grow at a CAGR of 16%.

Constantly the average age for taking up pregnancy by women across the globe has increased significantly. Babies being born with genetic disorders including Down syndrome, Turner syndrome, Edwards syndrome, and others are now more likely as a result of this phenomenon.

The development of non-invasive prenatal testing made it possible to safely identify such fetal defects.

Access the sample report: https://www.insightslice.com/request-sample/531

Global Non-Invasive Prenatal Testing Market Key Segments:

By Technique:

  • Polymerase Chain Reaction (PCR)
  • Next-generation Sequencing (NGS)
  • Others

By Application:

  • Down Syndrome
  • Edwards Syndrome
  • Turner Syndrome
  • Patau Syndrome
  • Others

By Testing Venue:

  • Hospital
  • Diagnostics Centers
  • Others

By Geography

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Belgium
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

The key players of the Global Non-Invasive Prenatal Testing Market are:

Main competitors covered in the Global Cold Laser Therapy Market report include Berry Genomics, Natera, Illumina, Eurofins Biomnis, Lilac Insights Pvt. Ltd., BGI Genomics, LabCorp, F. Hoffmann-La Roche Ltd., Medgenome Claria, GENDIA, Dante Labs, LifeLabs Genetics, and Sequenom.

Read more about the report inclusions: https://www.insightslice.com/non-invasive-prenatal-testing-market

A straightforward blood test, which is non-invasive, makes it possible to tackle the difficult process of discovering any genetic anomalies. This method is non-invasive and produces reliable findings.

The test can be effectively performed as early as the first trimester of pregnancy and is a straightforward blood test. The number of newborns born worldwide with genetic defects has also increased as a result of the changing lifestyles of the masses.

Pregnancy neglect may also result in irreparable problems in newborn children. Technology advancements have pushed users to select non-invasive prenatal testing methods to obtain the required tests in advance.

Effects of government regulations:

The essential reimbursement policies and enabling government programs make sure that everyone is aware of non-invasive prenatal testing. The non-invasive prenatal testing is less accurate than the invasive and other alternative techniques, which are still used in the industry.

Additionally, the price of non-invasive diagnostics is rather high. But over the projected period, the expansion of the non-invasive prenatal testing market is anticipated to be aided by the ongoing advancement of genome sequencing technology.

The majority of international players are making significant investments in R&D to advance NIPT approaches. These efforts will be fruitful, and during the projected period, a solid growth rate is anticipated for demand for non-invasive prenatal testing.

High potential for indirect growth exists due to next-generation sequencing technology:

The Next-Generation Sequencing (NGS) approach is favored by doctors for the early and precise detection of genetic abnormalities due to the technological improvement it has undergone.

NGS is thought to offer a platform for finding cfDNA that is circulating in the blood. NGS technology is used by many top companies, including Illumina, in their non-invasive prenatal testing kits. They assert that with the use of whole-genome sequencing, test failure rates continue to be incredibly low.

North America is a leader in revenue-generating thanks to the increased use of minimally invasive diagnostics:

North America accounts for more than half of the world’s NIPT demand. The demand for non-invasive prenatal testing increased as there were more infants in the United States with genetic diseases.

Additionally, minimally invasive diagnostic techniques are widely used in North America. The availability of cutting-edge technology through diagnostics centers and expanded payer coverage for pregnancy risks are beneficial for the expansion of NIPT in North America.

The advantages of early diagnosis and minimally invasive diagnostic procedures are becoming more well-known among the population in the Asia-Pacific area. This guarantees steady market growth for non-invasive prenatal testing in the area.

Related reports:

Global 3D Cell Culture Market: https://www.insightslice.com/3d-cell-culture-market

Global CRISPR and Cas Genes Market: https://www.insightslice.com/crispr-and-cas-genes-market

The most frequent application is for Down Syndrome due to high incidence:

One of the most common uses of non-invasive prenatal testing is for the detection of Down syndrome. This is because Down Syndrome affects the majority of newborns worldwide and is a chromosomal condition.

According to data provided by the Centers for Disease Control and Prevention (CDC), this illness affects roughly 1 in 700 newborns.

Non-invasive prenatal testing is essential for a pregnant woman to undergo during the first trimester to screen for the syndrome. It is expected that this application category, which now dominates the global NIPT market, will continue to hold sway over the coming years.

Diagnostics Centers make significant financial contributions to the wider economy:

Both diagnostic facilities and hospitals use non-invasive prenatal testing. Although hospitals have traditionally been a major source of revenue, independent diagnostics facilities have a lot of promise.

Diagnostics facilities have been expanding the number and caliber of services they offer. End consumers want to have significant testing done at their reliable diagnostic facilities. Home service is part of Diagnostic Centers’ expanded service offering, which has aided in customer retention.

In contrast to earlier, the diagnostic centers are fully furnished for all premium testing. Throughout the forecast period, it is anticipated that the segment would experience reasonably strong growth.

Proceed to purchase: https://www.insightslice.com/buy-now/531

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at info@insightslice.com.

Contact us:

Alex R

+1 707 736 6633

alex@insightslice.com

https://www.insightslice.com/

Linkedin | Twitter

Editor Details

Last Updated: 14-Nov-2022